Dr. Bruce R. Kressel, MD

Dr. Kressel practices at Sibley Memorial Hospital in Washington, District of Columbia, part of Johns Hopkins Health System.

Dr. Kressel's NPI, 1497861025, was assigned on August 23, 2006. Dr. Kressel graduated from Tufts University School of Medicine in 1973. Dr. Kressel holds District of Columbia license MD 7655.

Dr. Kressel's primary practice is Sibley Memorial Hospital, at 5255 Loughboro Rd NW, Washington, DC 20016 in The District County. The practice phone is (202) 537-4680.

Dr. Kressel's primary practice is Sibley Memorial Hospital in Washington, District of Columbia, part of Johns Hopkins Health System. Dr. Kressel is also affiliated with MedStar Georgetown University Hospital. The medical group on file is Johns Hopkins University. Dmand AI also links Dr. Kressel to 1 more hospital, 1 home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kressel practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Kressel's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Kressel is licensed in District of Columbia.

CMS data shows 1,727 Medicare services from Dr. Kressel across 6 procedure codes in 2024, for 394 Medicare patients. Medicare paid $124,220 for them.

CMS counts 394 Medicare patients who saw Dr. Kressel in 2024. The largest group is 75 to 84, with 192 patients. 73% of them have high cholesterol, and 70% have high blood pressure. 5% are also on Medicaid. Their average risk score is 1.89, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kressel's median patient age at 78, with 56% women.

In 2024, Dr. Kressel wrote 890 Medicare Part D claims for 139 patients. 46% of them were for generic drugs. CMS names the drug for 757 of them, across 21 drugs with 11 or more claims each, at $6,729,070 in total drug cost. In 2023, CMS named 272 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Kressel for performance year 2024, reported as part of a group. Dr. Kressel accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kressel as offering telehealth.

Dmand AI links 4 papers to Dr. Kressel, published from 2015 to 2019. Dr. Kressel's most frequent co-authors are Michael Anthony Carducci, MD, David Z. Chu, MD and Samuel Ray Denmeade, MD.

Dmand AI links Dr. Kressel to 3 clinical trials, 2 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Breast Neoplasms, Male, Carcinoma, Non-Small-Cell Lung and Breast Neoplasms.

CMS Open Payments shows 1 general payment to Dr. Kressel from 1 drug or device company in 2022. Food and beverage make up the largest share, 100% of the total. GlaxoSmithKline, LLC. paid the most, $26.

Dr. Kressel graduated from Tufts University School of Medicine in 1973.